Study reveals less severity of Omicron BA.2, with fewer deaths and lower likelihood of hospitalizations and invasive procedures.
Department of Medicine
Nigwekar Lab: Sagar Nigwekar, MD, MMSc
Explore This Research Lab
My primary research focus is calciphylaxis (also known as calcific uremic arteriolopathy) and it aims to develop effective treatments and diagnostic tests for patients with calciphylaxis.Calciphylaxis, a dermal arteriolar calcification disorder, has significant mortality and morbidity. I am leading multiple research studies in calciphylaxis patients. These studies address risk factors and pathogenesis of calciphylaxis and guide development and examination of novel treatments and diagnostic modalities for this highly fatal disease. Our team is currently enrolling patients in the first ever randomized controlled trial for calciphylaxis wherein we are testing vitamin K supplementation as a potential therapy. More details regarding this trial are available at Clinicaltrials.gov.
Our team also aims to apply the knowledge gained from calciphylaxis research to investigate other forms of vascular calcifications.
I am also involved in the epidemiological and translational investigations in the areas of hyponatremia, nephrolithiasis and olfaction-malnutrition.Learn more about the Calciphylaxis Program at Mass General
- Nigwekar SU. An unusual case of nonhealing leg ulcer in a diabetic patient.South Med J. 2007; 100(8):851-2. PMID: 17713318.
- Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008; 3(4):1139-43. PMID: 18417747; PMCID: PMC2440281
- Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013; 8(7):1162-70. PMID: 23520041; PMCID: PMC3700696.
- Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013; 37(4):325-32. PMID: 23548843; PMCID: PMC4110510.
- Nigwekar SU, Wenger J, Thadhani R, Bhan I. Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study. Am J Kidney Dis. 2013; 62(4):755-62. PMID: 23591291; PMCID: PMC3972035.
- Strazzula L, Nigwekar SU, Steele D, Tsiaras W, Sise M, Bis S, Smith GP, Kroshinsky D. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013; 149(8):946-9. PMID: 23760631
- Allegretti AS, Nazarian RM, Goverman J, Nigwekar SU. Calciphylaxis: a rare but fatal delayed complication of Roux-en-Y gastric bypass surgery. Am J Kidney Dis. 2014;64(2):274-7. PMID: 24787764.
- Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggert W, Turchin A, Thadhani RI, Herzog CA. Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med. 2014;29 Suppl 3:S724-31. PMID: 25029979; PMCID: PMC4124115.
- Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015; 66(1):133-46. PMID: 25960299; PMCID: PMC4696752.
- Lloyd WR, Agarwal S, Nigwekar SU, Esmonde-White K, Loder S, Fagan S, Goverman J, Olsen BR, Jumlongras D, Morris MD, Levi B. Raman spectroscopy for label-free identification of calciphylaxis. J Biomed Opt. 2015; 20(8):80501. PMID: 26263412; PMCID: PMC4689104.
- Nigwekar SU. Multidisciplinary approach to calcific uremic arteriolopathy.Curr Opin Nephrol Hypertens. 2015; 24(6):531-7. PMID: 26371529.
- Paul S, Rabito CA, Vedak P, Nigwekar SU, Kroshinsky D. The Role of Bone Scintigraphy in the Diagnosis of Calciphylaxis. JAMA Dermatol. 2015 Dec 16. [Epub ahead of print] PMID: 26677101.
- Department of Medicine
Related News and Articles
- Oct | 12 | 2022
Research Spotlight: Microbial Bile Acid Metabolism Regulates Gut Barrier Integrity and Liver Injury and Could Be a New Treatment Target
Researchers looked at the impact of bacterial metabolism of host-produced bile acid (BA) metabolites on epithelial barrier integrity.
- Press Release
- Sep | 23 | 2022
The wrist-worn devices may identify patients who would benefit from stroke prevention therapies.
- Sep | 21 | 2022
Hydroxychloroquine dosing under 5 mg/kg/day is less effective in preventing lupus flares than higher dosing.
- Press Release
- Sep | 21 | 2022
Researchers from Mass General and colleagues have used an innovative organoid-on-a-chip model to identify new treatment targets for an inherited kidney disease that causes significant death and disability.
- Sep | 15 | 2022
Gout was more prevalent in adults self-reporting Black race during a recent 10-year period compared with their White counterparts.
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.